Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,310 | 7 | 96.6% |
| Travel and Lodging | $542.97 | 2 | 2.9% |
| Food and Beverage | $91.50 | 2 | 0.5% |
| Education | $12.76 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $18,853 | 9 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $69.74 | 1 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $21.76 | 1 | $0 (2021) |
| Travere Therapeutics, Inc. | $12.76 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $4,673 | 4 | Alnylam Pharmaceuticals Inc. ($4,603) |
| 2022 | $1,750 | 1 | Alnylam Pharmaceuticals Inc. ($1,750) |
| 2021 | $7,022 | 3 | Alnylam Pharmaceuticals Inc. ($7,000) |
| 2020 | $5,513 | 7 | Alnylam Pharmaceuticals Inc. ($5,500) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $519.80 | General |
| 11/02/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $69.74 | General |
| 11/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $4,060.00 | General |
| Category: Genetic Disease | ||||||
| 11/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | Cash or cash equivalent | $23.17 | General |
| Category: Genetic Disease | ||||||
| 12/09/2022 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Genetic Disease | ||||||
| 11/02/2021 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), XARELTO | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/29/2021 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Genetic Disease | ||||||
| 06/10/2021 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Genetic Disease | ||||||
| 12/22/2020 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Genetic Disease | ||||||
| 12/22/2020 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Genetic Disease | ||||||
| 08/13/2020 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Genetic Disease | ||||||
| 07/31/2020 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.19 | General |
| 07/31/2020 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.19 | General |
| 07/31/2020 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.19 | General |
| 07/31/2020 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.19 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 1 | 14 | 24 | $7,100 | $2,088 |
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 24 | $7,100 | $2,088 | 29.4% |
About Michael Moritz
Michael Moritz is a Pediatrics healthcare provider based in Akron, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710951470.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Moritz has received a total of $18,957 in payments from pharmaceutical and medical device companies, with $4,673 received in 2023. These payments were reported across 15 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($18,310).
As a Medicare-enrolled provider, Moritz has provided services to 14 Medicare beneficiaries, totaling 24 services with total Medicare billing of $2,088. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Nephrology, Pediatric Nephrology
- Location Akron, OH
- Active Since 02/17/2006
- Last Updated 10/11/2024
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1710951470
Products in Payments
- OXLUMO (Drug) $18,333
- INVOKANA (Drug) $21.76
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Akron
Dr. Jessica Castonguay, Do, DO
Pediatrics — Payments: $17,240
Paul Schuh, M.d, M.D
Pediatrics — Payments: $3,187
Dr. Roxanne Taylor, M.d, M.D
Pediatrics — Payments: $2,570
Dr. Robert Abood, M.d, M.D
Pediatrics — Payments: $2,484
Margaret Pfeffer, M.d, M.D
Pediatrics — Payments: $2,035
Dr. Matthew Wyneski, M.d, M.D
Pediatrics — Payments: $1,969